دورية أكاديمية
[Recombinant human interleukin-11 in the prevention of chemotherapy-induced thrombocytopenia].
| العنوان: | [Recombinant human interleukin-11 in the prevention of chemotherapy-induced thrombocytopenia]. |
|---|---|
| المؤلفون: | Chu DT; Department of Medical Oncology, Cancer Institute (Hospital), Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 100021, China., Xu BH, Song ST, Mao XH, Jiao SC, Zhang AL |
| المصدر: | Zhonghua zhong liu za zhi [Chinese journal of oncology] [Zhonghua Zhong Liu Za Zhi] 2003 May; Vol. 25 (3), pp. 272-4. |
| نوع المنشور: | Clinical Trial; English Abstract; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
| اللغة: | Chinese |
| بيانات الدورية: | Publisher: Chinese Medical Association Country of Publication: China NLM ID: 7910681 Publication Model: Print Cited Medium: Print ISSN: 0253-3766 (Print) Linking ISSN: 02533766 NLM ISO Abbreviation: Zhonghua Zhong Liu Za Zhi Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: Peking : Chinese Medical Association Original Publication: Beijing, Zhonghua yi xue hui. |
| مواضيع طبية MeSH: | Antineoplastic Agents/*adverse effects , Interleukin-11/*therapeutic use , Thrombocytopenia/*prevention & control, Adolescent ; Adult ; Aged ; Cross-Over Studies ; Double-Blind Method ; Humans ; Interleukin-11/adverse effects ; Middle Aged ; Neoplasms/blood ; Neoplasms/drug therapy ; Recombinant Proteins/therapeutic use |
| مستخلص: | Objective: To evaluate the efficacy and toxicity of domestic recombinant human interleukin-11 (rhIL-11) in the prevention of chemotherapy-induced thrombocytopenia. Methods: A randomized, self-crossover and placebo-controlled trial was conducted, with rhIL-11 and placebo classified randomly as drug A and drug B. Patients were randomly assigned to group AB or group BA. 25 microg/kg body weight of drug A or drug B was administered subcutaneously once daily starting 24 hours after chemotherapy and continued for 7 to 14 days or until the platelet count reached > or = 300 x 10(9)/L. Results: 118 patients were evaluable in the efficacy study. When compared with the placebo treated cycle, the results showed that rhIL-11 was able to significantly increase the platelet count at the nadir and d21 after chemotherapy, with a increase of 60.7% and 86.1% (both P < 0.001). The mean duration of thrombocytopenia (< 100 x 10(9)/L) in rhIL-11 treated cycle was 1.0 +/- 2.0 days as compared to 6.9 +/- 5.3 days in placebo treated cycle. The side effects were ache (24.6%), swelling (16.1%) and knurl (11.9%) at the injection site, hyperaemia of conjunctiva (16.1%), edema (8.5%), palpitation (6.8%) and fatigue (5.1%). Conclusion: rhIL-11, possessing significant thrompoietic activity, significantly increases the likelihood of avoiding chemotherapy-induced thrombocytopenia and shorten the duration of thrombocytopenia. Its side effects are mild and manageable. |
| المشرفين على المادة: | 0 (Antineoplastic Agents) 0 (Interleukin-11) 0 (Recombinant Proteins) |
| تواريخ الأحداث: | Date Created: 20030704 Date Completed: 20100518 Latest Revision: 20030703 |
| رمز التحديث: | 20240627 |
| PMID: | 12839693 |
| قاعدة البيانات: | MEDLINE |
كن أول من يترك تعليقا!